The industry must brace for further pushback from lawmakers, regulators, and other stakeholders who, emboldened by the IRA victory, continue to try to rein in big pharma.
The pharma landscape is more volatile than ever before, and pushback on drug prices will continue to intensify from payers, PBMs and especially consumers.
It s clear that the push by policymakers to rein in the pharmaceutical industry through regulations that force lower drug prices shows no signs of slowing.